TY - JOUR
T1 - Eosinophilic esophagitis
T2 - Overview of clinical management
AU - Schoepfer, Alain M.
AU - Hirano, Ikuo
AU - Katzka, David A.
N1 - Funding Information:
Disclosures: A.M. Schoepfer received consulting fees and/or speaker fees and/or research grants from AstraZeneca , AG, Switzerland, Aptalis Pharma , Inc, Dr Falk Pharma , GmbH, Germany, Glaxo Smith Kline , AG, Nestlé S. A. , Switzerland, and Novartis , AG, Switzerland. D.A. Katzka has no relevant financial, professional, or personal relationships to disclose. I. Hirano received consulting fees and/or speaker fees and/or research grants from Meritage Pharma , Inc, Aptalis Pharma , Inc, and Receptos, Inc .
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2014/6
Y1 - 2014/6
N2 - A validated disease-specific symptom-assessment tool for eosinophilic esophagitis (EoE) has yet to be approved by regulatory authorities for use in clinical trials. Relevant end points for daily practice include EoE-related symptoms and esophageal eosinophilic inflammation. Endoscopic features should also be taken into account when establishing a therapy plan. A reasonable clinical goal is to achieve a reduction in EoE-related symptoms and esophageal eosinophilic inflammation. Evidence is increasing to support an anti-inflammatory maintenance therapy, as this can reduce esophageal remodeling. In EoE patients in clinical remission, annual disease monitoring with symptom, endoscopic, and histologic assessments of sustained treatment response is recommended.
AB - A validated disease-specific symptom-assessment tool for eosinophilic esophagitis (EoE) has yet to be approved by regulatory authorities for use in clinical trials. Relevant end points for daily practice include EoE-related symptoms and esophageal eosinophilic inflammation. Endoscopic features should also be taken into account when establishing a therapy plan. A reasonable clinical goal is to achieve a reduction in EoE-related symptoms and esophageal eosinophilic inflammation. Evidence is increasing to support an anti-inflammatory maintenance therapy, as this can reduce esophageal remodeling. In EoE patients in clinical remission, annual disease monitoring with symptom, endoscopic, and histologic assessments of sustained treatment response is recommended.
KW - Dysphagia
KW - Eosinophilic esophagitis
KW - Gastroesophageal reflux disease
KW - Patient-reported outcomes
KW - Treatment end points
UR - http://www.scopus.com/inward/record.url?scp=84899956778&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899956778&partnerID=8YFLogxK
U2 - 10.1016/j.gtc.2014.02.014
DO - 10.1016/j.gtc.2014.02.014
M3 - Review article
C2 - 24813519
AN - SCOPUS:84899956778
SN - 0889-8553
VL - 43
SP - 329
EP - 344
JO - Gastroenterology Clinics of North America
JF - Gastroenterology Clinics of North America
IS - 2
ER -